An open-label, multicenter, phase I/II study of JNJ-40346527, a CSF-1R inhibitor, in patients with relapsed or refractory Hodgkin lymphoma

Clinical Cancer Research

Volumn 21, Issue 8, 2015, Pages 1843-1850

  Von Tresckow, Bastian ^a   Morschhauser, Franck ^b   Ribrag, Vincent ^c   Topp, Max S ^d   Chien, Caly ^e   Seetharam, Shobha ^f   Aquino, Regina ^f   Kotoulek, Sonja ^f   De Boer, Carla J ^g   Engert, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^f JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^g Janssen Biologics   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR 1 RECEPTOR; JNJ 40346527; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; COLONY STIMULATING FACTOR RECEPTOR; IMIDAZOLE DERIVATIVE; JNJ-40346527; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONSTIPATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENZYME DEFECT; FATIGUE; FEMALE; FEVER; HEADACHE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; LARYNGITIS; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OROPHARYNX PAIN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STOMACH OBSTRUCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; VOMITING; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; PATHOLOGY; RETREATMENT; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS; FEMALE; HODGKIN DISEASE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; RETREATMENT; TREATMENT OUTCOME;

EID: 84927619096     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1845     Document Type: Article

References (43)

1. Engert A, Haverkamp H, Kobe C, Markova J, Renner C,Ho A, et al. Reducedintensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012;379:1791-9.
2. Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640-52.
3. Quddus F, Armitage JO. Salvage therapy for Hodgkin's lymphoma. Cancer J 2009;15:161-3.
4. Rathore B, Kadin ME. Hodgkin's lymphoma therapy: past, present, and future. Expert Opin Pharmacother 2010;11:2891-906.
5. Sureda A, Pereira MI, Dreger P. The role of hematopoietic stem cell transplantation in the treatment of relapsed/refractory Hodgkin's lymphoma. Curr Opin Oncol 2012;24:727-32.
6. Copeland A, Younes A. Current treatment strategies in Hodgkin lymphomas. Curr Opin Oncol 2012;24:466-74.
7. von Tresckow B, Engert A. Refractory Hodgkin lymphoma. Curr Opin Oncol 2013;25:463-9.
8. Boll B, Goergen H, Arndt N, Meissner J, Krause SW, Schnell R, et al. Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group. J Clin Oncol 2013;31:4431-7.
9. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30: 2183-9.
10. Gopal AK, Chen R, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Three-year follow-up data and characterization of long-term remissions from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory hodgkin lymphoma [abstract]. In: Proceedings of the ASH; 2013;122. Abstract nr. 4382.
11. Lamprecht B, Walter K, Kreher S, Kumar R, Hummel M, Lenze D, et al. Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med 2010;16:571-9.
12. Paietta E, Racevskis J, Stanley ER, Andreeff M, Papenhausen P, Wiernik PH. Expression of the macrophage growth factor, CSF-1 and its receptor c-fms by a Hodgkin's disease-derived cell line and its variants. Cancer Res 1990;50:2049-55.
13. Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, et al. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat 2011;128:703-11.
14. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-8.
15. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011;29:1812-26.
16. Filderman AE, Bruckner A, Kacinski BM, Deng N, Remold HG. Macrophage colony-stimulating factor (CSF-1) enhances invasiveness in CSF-1 receptor- positive carcinoma cell lines. Cancer Res 1992;52:3661-6.
17. Koh YW, Park C, Yoon DH, Suh C, Huh J. CSF-1R expression in tumorassociated macrophages is associated with worse prognosis in classical hodgkin lymphoma. Am J Clin Pathol 2014;141:573-83.
18. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001;193:727-40.
19. Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol 2004;14:628-38.
20. Manthey CL, Johnson DL, Illig CR, Tuman RW, Zhou Z, Baker JF, et al. JNJ- 28312141, a novel orally active colony-stimulating factor-1 receptor/FMSrelated receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther 2009;8:3151-61.
21. Deau B, Bachy E, Ribrag V, Delarue R, Rubio MT, Bosq J, et al. Macrophage, mast cell and T lymphocyte infiltrations are independent predictive biomarkers of primary refractoriness or early relapse in classical Hodgkin lymphoma. Leuk Lymphoma 2013;54:41-5.
22. Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, Nyengaard JR, d'Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011;96:269-76.
23. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006;66:11238-46.
24. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011;1:54-67.
25. Pileri SA, Ascani S, Leoncini L, Sabattini E, Zinzani PL, Piccaluga PP, et al. Hodgkin's lymphoma: the pathologist's viewpoint. J Clin Pathol 2002;55: 162-76.
26. Brauninger A, Schmitz R, Bechtel D, Renne C, Hansmann ML, Kuppers R. Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. Int J Cancer 2006;118:1853-61.
27. Janz M, Dorken B, Mathas S. Reprogramming of B lymphoid cells in human lymphoma pathogenesis. Cell Cycle 2006;5:1057-61.
28. Moreau A, Praloran V, Berrada L, Coupey L, Gaillard F. Immunohistochemical detection of cells positive for colony-stimulating factor 1 in lymph nodes from reactive lymphadenitis, and Hodgkin's disease. Leukemia 1992;6:126-30.
29. Campion L, DeAngelis N, Ferrante C, Verona R, Seetharam S, Manthey C, et al. Effects of blocking aberrantly expressed CSF-1R in Hodgkin lymphoma. Poster presented at AACR-NCI-EORTC Meeting; 2013; Oct 19-23.
30. Cheson BD, P fistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
31. Chaturvedi S, Dell E, Siegel D, Brittingham G, Seetharam S. Development of a rapid streptavidin capture-based assay for the tyrosine phosphorylated CSF-1R in peripheral blood mononuclear cells. Int J Biol Sci 2013;9: 1099-107.
32. Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007; 92:35-41.
33. Martinez C, Canals C, Sarina B, Alessandrino EP, Karakasis D, Pulsoni A, et al. Identi fication of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol 2013;24:2430-4.
34. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507-16.
35. von Tresckow B, Diehl V. An update on emerging drugs for Hodgkin lymphoma. Expert Opin Emerg Drugs 2014;19:215-24.
36. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38.
37. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-34.
38. Motzer RJ, Hutson TE, Tomczak P, MichaelsonMD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patientswith metastatic renal cell carcinoma. JClin Oncol 2009;27:3584-90.
39. Kogan M, Fischer-Smith T, Kaminsky R, Lehmicke G, Rappaport J. CSF-1R up-regulation is associated with response to pharmacotherapy targeting tyrosine kinase activity in AML cell lines. Anticancer Res 2012;32:893-9.
40. Morandi A, Barbetti V, Riverso M, Dello Sbarba P, Rovida E. The colonystimulating factor-1 (CSF-1) receptor sustains ERK1/2 activation and proliferation in breast cancer cell lines. PLoS ONE 2011;6:e27450.
41. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003;20:757-66.
42. Schatz JH, Wendel HG. Targeted cancer therapy: what if the driver is just a messenger? Cell Cycle 2011;10:3830-3.
43. Sulkes A. Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm. Isr Med Assoc J 2010;12:628-32.